Jon Faulkes

Jon Faulkes, formerly business development manager, formulation development, Aesica Pharmaceuticals

Articles

September 2nd 2014

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

Latest Updated Articles

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

Published: February 23rd 2024 | Updated: December 22nd 2024

Europa Perspectives: Helping to Navigate the Regulatory System

Published: December 13th 2024 | Updated: December 22nd 2024

FDA Creates CDER Center for Real-World Evidence Innovation

Close-up of a microscope lens examining microarray slides, a crucial tool in genomic research and medical diagnostics | Image Credit: © Varunee - Stock.Adobe.com

Published: December 5th 2024 | Updated: December 22nd 2024

Leveraging Advancements in Bioanalytical Testing

Lipid nanoparticle siRNA antiviral delivery system, 3D illustration | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com

Published: December 7th 2024 | Updated: December 22nd 2024

Exploring Opportunities for LNP Delivery in mRNA

About Us

Advertise

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777